Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 – PRISM MediaWire – ANEW MEDICAL, INC. (NASDAQ: WENA),
Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology
New York, NY. August 21, 2024 – ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement
New York, NY, August 19, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and
Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S. New York, NY, August 15,
NEW YORK, NY, August 09, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA) has announced that, as a result of its worldwide licensing agreement with Teleost
New York, NY, August 8, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and
Genomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and
Collaboration focuses on research and development of ANEW’s patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW’s mission is to deliver transformative
NEW YORK, June 26, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW” or “the Company”) a biopharmaceutical company specializing in the advancement of novel disease-modifying
PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850
